Journal
BRITISH JOURNAL OF CANCER
Volume 97, Issue 6, Pages 730-734Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603944
Keywords
prostate cancer; MUC-1; population-based; prognostic marker; twenty year follow-up; anti-adhesion
Categories
Funding
- NCI NIH HHS [T32 CA009001] Funding Source: Medline
Ask authors/readers for more resources
Anti-adhesion mucins have proven to play an important part in the biology of several types of cancer. Therefore, we test the hypothesis that altered expression of MUC-1 is associated with prostate cancer progression. We retrieved archival tumour tissue from a population-based cohort of 195 men with localised prostate cancer (T1a-b, Nx, M0) that has been followed for up to 20 years with watchful waiting. Semi-automated, quantitative immunohistochemistry was undertaken to evaluate MUC-1 expression. We modelled prostate cancer-specific death as a function of MUC-1 levels accounting for age, Gleason grade and tumour extent, and calculated age-adjusted and multivariate adjusted hazard ratios (HR). Men that had tumours with an MUC-intensity lower or higher than normal tissue had a higher risk of dying in prostate cancer, independent of tumour extent and Gleason score (HR 5.1 and 4.5, respectively). Adjustment for Gleason grade and tumour stage did not alter the results. Men with a Gleason score >= 7 and MUC-1 deviating from the normal had a 17 (RR = 17.1 95% confidence interval = 2.3-128) times higher risk to die in prostate cancer compared with men with Gleason score < 7 and normal MUC-1 intensity. In summary, our data show that MUC-1 is an independent prognostic marker for prostate cancer death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available